Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Apr. 29, 2025 11:30 AM ET, , , , , , , , , , , ,
Baron Capital
333 Followers
(7min)

Summary

  • Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth.
  • Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs.
  • UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
  • Arcellx, Glaukos, and Intuitive Surgical faced setbacks due to trial uncertainties, reimbursement issues, and tariff concerns, but long-term growth prospects remain strong.

Abstract technology background with binary code, US dollars and a stethoscope

Viorika

The following segment was excerpted from the Baron Health Care Fund Q1 2025 Shareholder Letter.


Top Contributors to Performance

Table II: Top contributors to performance for the quarter ended March 31, 2025

Contribution to Return (%)
Boston

This article was written by

333 Followers
Baron is an asset management firm focused on delivering growth equity investment solutions. Founded in 1982, Baron has become known for its long-term, fundamental, active approach to growth investing. Baron was founded as an equity research firm, and research has remained at the core of its business. Note: This account is not managed or monitored by Baron Capital, and any messages sent via Seeking Alpha will not receive a response. For inquiries or communication, please use Baron Capital's official channels.

Recommended For You

Related Stocks

SymbolLast Price% Chg
BSX--
Boston Scientific Corporation
VRTX--
Vertex Pharmaceuticals Incorporated
UNH--
UnitedHealth Group Incorporated
LLY--
Eli Lilly and Company
INSM--
Insmed Incorporated

Related Analysis